Undoubtedly, anti-obesity treatment is currently the hottest topic in the biomedical drug research and development field
GLP-1 RAs act via both peripheral and central mechanisms
Increased Focus On Preventive Care - The increased focus on preventive care as a major factor driving the expansion of the GLP-1 receptor agonist market by 2030
Dose optimization, genetic testing, or compound switching often resolves the plateau and restarts weight loss progress
In clinical trials, significant weight loss was observed within several weeks to a few months of starting treatment
Recientemente, un estudio internacional revel que cuatro de cada diez argentinos con diabetes tipo 2 tienen, adems, enfermedad cardiovascular [9], que es la principal causa de muerte y discapacidad en este tipo de diabetes [10]